A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin

@article{Gray2015AFP,
  title={A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin},
  author={Jhanelle E Gray and Jeffrey R. Infante and Les H. Brail and George Rajan Simon and Jennifer F. Cooksey and Suzanne Fields Jones and Daphne L. Farrington and Adeline A Yeo and Kimberley A. Jackson and Kay Hoong Chow and Maciej J. Zamek-Gliszczynski and Howard A. Burris},
  journal={Investigational New Drugs},
  year={2015},
  volume={33},
  pages={1187-1196}
}
Purpose LY2090314 (LY) is a glycogen synthase kinase 3 inhibitor with preclinical efficacy in xenograft models when combined with platinum regimens. A first-in-human phase 1 dose-escalation study evaluated the combination of LY with pemetrexed/carboplatin. Patients and Methods Forty-one patients with advanced solid tumors received single-dose LY monotherapy lead-in and 37 patients received LY (10–120 mg) plus pemetrexed/carboplatin (500 mg/m2 and 5–6 AUC, respectively) across 8 dose levels… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Guidelines in Oncology (NCCN Guidelines®): Malignant pleural mesothelioma

  • NCCN Clinical Practic
  • Version 1:
  • 2013
Highly Influential
7 Excerpts

Guidelines in Oncology (NCCN Guidelines®): Non-small cell lung cancer

  • NCCN Clinical Practic
  • Version 2:
  • 2013
Highly Influential
7 Excerpts

Similar Papers

Loading similar papers…